Irene Malaty

A phase 2a multicenter, randomized, double-blinded, placebo-controlled multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson’s disease (PD).

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson’s Disease

Tourette Association of America - Community Engagement Award

A Global Real-World Evidence Study on the long-term effectiveness of ABBV-951 in Advanced Parkinson’s Disease in routine clinical practice (ROSSINI: Real-world Outcomes with continuouS Subcutaneous levodopa INfusIon

Ecopipam, encoded EBS-101-TD-391 entitled “A Multicenter, Open-Label, Study to Evaluate the Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults with Tourette’s Disorder”

Parkinson s Foundation 2025-26 Global Care Network Award

Parkinson’s Foundation FY24 Center of Excellence Award

AN OPEN-LABEL STUDY OF THE LONG-TERM SAFETY AND TOLERABILITY OF SAGE-324 IN PARTICIPANTS WITH ESSENTIAL TREMOR

Parkinson’s Foundation PD GENEration Genetic Registry

A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Maintenance of Efficacy of Ecopipam in Children, Adolescents and Adults with Tourette’s Disorder

A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RESPONSE STUDY OF SAGE-324 FOR THE TREATMENT OF ESSENTIAL TREMOR

UF CoE Community Education Grant (TAA) 2023

Progressive resistance exercise and dystonia pathophysiology.

PF COE PCORI Addtl. Support

Parkinson Foundation Center of Excellence 2022-2023

CTOA Malaty

Parkinson’s Foundation Center of Excellence Palliative Care Training Grant Award

Parkinson’s Disease Outreach Program to African Americans in Alachua County

Parkinson's Foundation COE award

An Open-Label Extension Of Study M15-736 To Evaluate The Safety And Tolerability Of 24-Hour Daily Exposure Of ABBV-951 In Subjects With Advanced Parkinson's Disease

A multicenter, randomized, active-controlled, double-blind, double dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless)

Parkinson Foundation Center of Excellence 2020-2021

A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients

A Randomized, Double-Blind, Placebo Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ABBV-0805 in Patients with Parkinson's Disease

2020 Educational Partnership Symposium COE